Logo image of TARA

PROTARA THERAPEUTIC INC (TARA) Stock Fundamental Analysis

NASDAQ:TARA - Nasdaq - US74365U1079 - Common Stock - Currency: USD

3.48  +0.06 (+1.75%)

After market: 3.48 0 (0%)

Fundamental Rating

3

Taking everything into account, TARA scores 3 out of 10 in our fundamental rating. TARA was compared to 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TARA as it has an excellent financial health rating, but there are worries on the profitability. TARA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TARA has reported negative net income.
TARA had a negative operating cash flow in the past year.
In the past 5 years TARA always reported negative net income.
In the past 5 years TARA always reported negative operating cash flow.
TARA Yearly Net Income VS EBIT VS OCF VS FCFTARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.58%, TARA is in the better half of the industry, outperforming 72.19% of the companies in the same industry.
TARA has a better Return On Equity (-26.68%) than 80.21% of its industry peers.
Industry RankSector Rank
ROA -24.58%
ROE -26.68%
ROIC N/A
ROA(3y)-45.59%
ROA(5y)-73.53%
ROE(3y)-50.98%
ROE(5y)-80.84%
ROIC(3y)N/A
ROIC(5y)N/A
TARA Yearly ROA, ROE, ROICTARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

TARA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARA Yearly Profit, Operating, Gross MarginsTARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TARA has been increased compared to 1 year ago.
Compared to 5 years ago, TARA has more shares outstanding
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TARA Yearly Shares OutstandingTARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TARA Yearly Total Debt VS Total AssetsTARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

TARA has an Altman-Z score of 3.81. This indicates that TARA is financially healthy and has little risk of bankruptcy at the moment.
TARA has a better Altman-Z score (3.81) than 77.90% of its industry peers.
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.81
ROIC/WACCN/A
WACCN/A
TARA Yearly LT Debt VS Equity VS FCFTARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

TARA has a Current Ratio of 15.71. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.
TARA has a better Current ratio (15.71) than 90.37% of its industry peers.
TARA has a Quick Ratio of 15.71. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 15.71, TARA belongs to the best of the industry, outperforming 90.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.71
Quick Ratio 15.71
TARA Yearly Current Assets VS Current LiabilitesTARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

TARA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.74%, which is quite impressive.
EPS 1Y (TTM)53.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.12% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.37%
EPS Next 2Y8.11%
EPS Next 3Y4.65%
EPS Next 5Y19.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TARA Yearly Revenue VS EstimatesTARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
TARA Yearly EPS VS EstimatesTARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TARA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARA Price Earnings VS Forward Price EarningsTARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARA Per share dataTARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.11%
EPS Next 3Y4.65%

More info and screens

0

5. Dividend

5.1 Amount

TARA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTARA THERAPEUTIC INC

NASDAQ:TARA (5/20/2025, 8:00:01 PM)

After market: 3.48 0 (0%)

3.48

+0.06 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners85.9%
Inst Owner Change1.02%
Ins Owners3.82%
Ins Owner Change2.15%
Market Cap134.26M
Analysts83.33
Price Target22.85 (556.61%)
Short Float %6.65%
Short Ratio6.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.35%
Min EPS beat(2)5.73%
Max EPS beat(2)14.97%
EPS beat(4)3
Avg EPS beat(4)15.55%
Min EPS beat(4)-3.37%
Max EPS beat(4)44.85%
EPS beat(8)6
Avg EPS beat(8)9.69%
EPS beat(12)8
Avg EPS beat(12)-0.09%
EPS beat(16)10
Avg EPS beat(16)-3.56%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.4%
PT rev (3m)-20%
EPS NQ rev (1m)5.34%
EPS NQ rev (3m)25.29%
EPS NY rev (1m)0%
EPS NY rev (3m)20.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-1.73
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS4.33
TBVpS4.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.58%
ROE -26.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.59%
ROA(5y)-73.53%
ROE(3y)-50.98%
ROE(5y)-80.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.71
Quick Ratio 15.71
Altman-Z 3.81
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)187.07%
Cap/Depr(5y)289.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.1%
EPS Next Y31.37%
EPS Next 2Y8.11%
EPS Next 3Y4.65%
EPS Next 5Y19.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.94%
OCF growth 3YN/A
OCF growth 5YN/A